Fig. 6

High ADGRA2 or ADRB3 expression is associated with worse NAC response and prognosis of BC patients. A The SCNA signal profiles identified by the GISTIC2.0 in the nonresponsive and responsive pre-treatment tumors. The significantly altered chromosome regions (q < 0.01) and the gene loci (ADGRA2, ADRB3 and FOXP1) are annotated. The mRNA expression level of ADGRA2 (B), ADRB3 (C), and FOXP1 (D) in the nonresponsive and responsive pre-treatment tumors from the RNA-seq data were shown as transcripts per million (TPM). E Representative immunohistochemistry staining of tumors with low and high expression of ADGRA2 and ADRB3 in the NACBC validation set (n = 156). Magnification: 400 × ; Bar, 100 μm. F Kaplan–Meier analyses of the DFS and BCSS in the NACBC validation set. Patients were stratified as high and low protein expression of ADGRA2 and ADRB3. P values were calculated based on the log-rank test